Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(23):1680-1681; doi:10.1093/jnci/djj509
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

New Method Found To Trigger Cancer Cell Suicide

Ken Garber

The first 10% of the full text of this article appears below.

Paul Hergenrother, Ph.D., is a 34-year-old chemist whose University of Illinois lab in Urbana is working on solving antibiotic resistance, neurodegenerative disease, and cancer. These are among the toughest unsolved problems in medicine, but that's why Hergenrother is drawn to them. "If we're all going to spend a lot of time doing something, we might as well do something important," he said.

The common element in Hergenrother's work is the use of small molecules to define new targets and create potential new drugs. In the October issue of Nature Chemical Biology, his group described what appears to be the first small-molecule activator of procaspase-3, a key enzyme in the apoptotic cascade that leads cells to commit suicide. They showed that the compound . . . [Full Text of this Article]

More Target, Less Drug

Pondering the Risks

Feeling Validated


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?